Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Debt to Equity (2016 - 2017)

Corcept Therapeutics' Debt to Equity history spans 2 years, with the latest figure at $0.07 for Q2 2017.

  • For Q2 2017, Debt to Equity fell 92.05% year-over-year to $0.07; the TTM value through Jun 2017 reached $0.07, down 92.05%, while the annual FY2016 figure was $0.35, N/A changed from the prior year.
  • Debt to Equity for Q2 2017 was $0.07 at Corcept Therapeutics, down from $0.2 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.24 in Q1 2016 and bottomed at $0.07 in Q2 2017.